Mineralys Therapeutics, Inc.

NasdaqGS:MLYS Stock Report

Market Cap: US$668.8m

Mineralys Therapeutics Future Growth

Future criteria checks 0/6

Mineralys Therapeutics's earnings are forecast to decline at 8.7% per annum while its annual revenue is expected to grow at 81.1% per year. EPS is expected to grow by 0.3% per annum.

Key information

-8.7%

Earnings growth rate

0.3%

EPS growth rate

Biotechs earnings growth27.3%
Revenue growth rate81.1%
Future return on equityn/a
Analyst coverage

Good

Last updated31 Oct 2024

Recent future growth updates

No updates

Recent updates

Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation

Oct 07
Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation

Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning

Sep 17

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Jun 06
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Mineralys Therapeutics: A Story To Keep An Eye On

Mar 18

Mineralys: 2nd Half 2024 Hypertension Data Readout

Feb 09

We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely

Nov 12
We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Jul 03
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Earnings and Revenue Growth Forecasts

NasdaqGS:MLYS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202614-192-202N/A4
12/31/2025N/A-182-206N/A4
12/31/2024N/A-154-180N/A4
6/30/2024N/A-120-97-97N/A
3/31/2024N/A-91-88-88N/A
12/31/2023N/A-72-81-81N/A
9/30/2023N/A-57-62-62N/A
6/30/2023N/A-40-50-50N/A
3/31/2023N/A-35-35-35N/A
12/31/2022N/A-30-29-29N/A
9/30/2022N/A-28-24-24N/A
12/31/2021N/A-19-15-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MLYS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MLYS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MLYS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MLYS is forecast to have no revenue next year.

High Growth Revenue: MLYS is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MLYS's Return on Equity is forecast to be high in 3 years time


Discover growth companies